$466 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 64 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | INVESCO QQQ TRcall | $61,510,680 | – | 231,000 | +100.0% | 13.20% | – | |
| New | ASTRIA THERAPEUTICS INC | $6,988,473 | – | 469,340 | +100.0% | 1.50% | – | |
| New | TOWER SEMICONDUCTOR LTDput | $6,981,120 | – | 161,600 | +100.0% | 1.50% | – | |
| FIVN | New | FIVE9 INC | $6,446,600 | – | 95,000 | +100.0% | 1.38% | – |
| XBI | New | SPDR SER TRs&p biotech | $5,810,000 | – | 70,000 | +100.0% | 1.25% | – |
| GNRC | New | GENERAC HLDGS INC | $5,032,995 | – | 50,000 | +100.0% | 1.08% | – |
| KNSA | New | KINIKSA PHARMACEUTICALS LTD | $4,603,099 | – | 307,283 | +100.0% | 0.99% | – |
| New | LEONARDO DRS INC | $4,288,418 | – | 335,557 | +100.0% | 0.92% | – | |
| New | APELLIS PHARMACEUTICALS INCput | $3,102,600 | – | 60,000 | +100.0% | 0.67% | – | |
| CAMT | New | CAMTEK LTDord | $2,415,600 | – | 110,000 | +100.0% | 0.52% | – |
| BCAB | New | BIOATLA INC | $1,539,450 | – | 186,600 | +100.0% | 0.33% | – |
| New | MEDIWOUND LTD | $1,017,321 | – | 75,413 | +100.0% | 0.22% | – | |
| AUTL | New | AUTOLUS THERAPEUTICS PLCspon ads | $950,000 | – | 500,000 | +100.0% | 0.20% | – |
| AMAT | New | APPLIED MATLS INC | $827,558 | – | 8,499 | +100.0% | 0.18% | – |
| TBLA | New | TABOOLA.COM LTD | $369,600 | – | 120,000 | +100.0% | 0.08% | – |
| AGLE | New | AEGLEA BIOTHERAPEUTICS INC | $198,333 | – | 440,837 | +100.0% | 0.04% | – |
| DYN | New | DYNE THERAPEUTICS INC | $82,857 | – | 7,149 | +100.0% | 0.02% | – |
| New | 89BIO INCcall | $45,828 | – | 3,600 | +100.0% | 0.01% | – | |
| New | OUTBRAIN INC | $43,976 | – | 12,148 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.